Aigen Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Aigen Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.89M	Buy	4,238 +3,344	+374%	+$1.56M	0.49%	55
2025 Q4	$405K	Buy	+894	New	+$385K	0.09%	283
2024 Q3	–	Sell	-1,274	Closed	-$597K	–	1042
2024 Q2	$597K	Buy	+1,274	New	+$553K	0.12%	254
2023 Q3	–	Sell	-4,358	Closed	-$1.53M	–	1105
2023 Q2	$1.53M	Buy	+4,358	New	+$1.47M	0.23%	127
2022 Q4	–	Sell	-6,692	Closed	-$1.94M	–	794
2022 Q3	$1.94M	Buy	6,692 +5,436	+433%	+$1.56M	0.28%	109
2022 Q2	$354K	Buy	+1,256	New	+$336K	0.06%	364
2022 Q1	–	Sell	-4,059	Closed	-$867K	–	1123
2021 Q4	$867K	Sell	4,059 -5,465	-57%	-$1.06M	0.05%	463
2021 Q3	$1.73M	Sell	9,524 -20,607	-68%	-$4.02M	0.33%	83
2021 Q2	$6.08M	Buy	+30,131	New	+$6.3M	1.06%	16
2020 Q4	–	Sell	-20,899	Closed	-$5.69M	–	1099
2020 Q3	$5.69M	Sell	20,899 -7,804	-27%	-$2.15M	0.73%	9
2020 Q2	$8.33M	Buy	28,703 +1,489	+5%	+$404K	1.07%	2
2020 Q1	$6.48M	Buy	27,214 +8,037	+42%	+$1.84M	0.86%	6
2019 Q4	$4.2M	Buy	+19,177	New	+$3.88M	0.7%	15

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Aigen Investment Management's VRTX Position: Q1 2026 in Review

Aigen Investment Management increased its Vertex Pharmaceuticals (VRTX) stake by 374% in Q1 2026, buying an estimated $1.56M and bringing the position to 4,238 shares worth $1.89M. The position accounts for 0.49% of the portfolio, ranked #55.

Aigen Investment Management first reported a position in VRTX in Q4 2019 and has held it in 13 quarters since. The position peaked at $8.33M in Q2 2020. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Aigen Investment Management held 4,238 shares of Vertex Pharmaceuticals worth $1.89M as of Q1 2026.
Aigen Investment Management bought 3,344 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1.56M.
Vertex Pharmaceuticals made up 0.49% of Aigen Investment Management's portfolio in Q1 2026, its #55 holding.
Aigen Investment Management first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 13 quarters since.
Aigen Investment Management's Vertex Pharmaceuticals position peaked at $8.33M in Q2 2020.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Aigen Investment Management's 13F filing for Q1 2026, filed 15 May 2026.